2024
DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology
Rahman R, Shi D, Reitman Z, Hamerlik P, de Groot J, Haas-Kogan D, D’Andrea A, Sulman E, Tanner K, Agar N, Sarkaria J, Tinkle C, Bindra R, Mehta M, Wen P. DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology. Neuro-Oncology 2024, 26: 1367-1387. PMID: 38770568, PMCID: PMC11300028, DOI: 10.1093/neuonc/noae072.Peer-Reviewed Original ResearchConsensus reviewDNA damage responseIDH wild-type glioblastomaIDH-mutant gliomasClinical trial design considerationsMechanisms of resistanceTrial design considerationsCombination therapyDevelopment of DDR inhibitorsDNA damage response pathwayPreclinical modelsDamage responseDDR inhibitorsNeuro-oncologyBrain tumorsBiomarker developmentTherapyResponse to DNA damageDNA damageTranslational effortsTumor
2020
Gray Areas in the Gray Matter: IDH1/2 Mutations in Glioma.
van den Bent MJ, Mellinghoff IK, Bindra RS. Gray Areas in the Gray Matter: IDH1/2 Mutations in Glioma. American Society Of Clinical Oncology Educational Book 2020, 40: 1-8. PMID: 32186930, PMCID: PMC7673204, DOI: 10.1200/edbk_280967.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMutant IDH inhibitorsIDH inhibitorsMutant acute myeloid leukemiaPhase III trialsDistinct clinical characteristicsClinical characteristicsIII trialsCombination therapyPharmacologic blockadeClinical trialsMutant cancer cellsMyeloid leukemiaDiagnostic groupsGray matterCancer developmentMetabolic changesAntitumor activityCancer cellsGliomasHuman cancersClass inhibitorMutant gliomasTumorsIntracellular changes